zagociguat
AssetAlso CY-6463, IW-6463
CNS-penetrant soluble guanylate cyclase (sGC) stimulator
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Oxidative phosphorylation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
Phase 2, Completed, NCT06402123, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials1
- Evidence for its targets4
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.